
MAIA Pharmaceuticals: Innovating and marketing niche generic products, specializing in injectables and oncology.
Founded in 2013 and headquartered in Princeton, New Jersey, MAIA Pharmaceuticals is a specialty pharmaceutical company dedicated to identifying, developing, manufacturing, and marketing innovative and niche generic products. The company focuses on providing injectables, diagnostics, hormones, and oncology treatments. MAIA Pharmaceuticals aims to address unmet medical needs by delivering high-quality and reliable pharmaceutical solutions to healthcare professionals across the United States.
MAIA Pharmaceuticals has established itself as a key player in the specialty generics market, with notable products such as the FDA-approved Sincalide for Injection, which boasts a 24-month shelf life. The company is backed by investors including Fosun Pharma, enhancing its capabilities and reach. MAIA's commitment to consistent supply and availability has significantly impacted the healthcare sector, ensuring that critical medications remain accessible to patients nationwide.

Meitheal Pharmaceuticals
meithealpharma.com

Eagle Pharmaceuticals
eagleus.com

Dawah Pharmaceuticals
dawahpharma.com

Manhattan Pharmaceuticals

Maipl Therapeutics
maipltx.com

US Specialty Formulations

Amneal Pharmaceuticals
amneal.com

6S Pharma
6spharma.com

Solaris Pharma
solaris-pharma.com

Leading Pharma
leadingpharma.com

American Injectables
americaninj.com

Eton Pharmaceuticals

Masters Pharmaceutical
mastersrx.com

Madeira Therapeutics

Amphastar Pharmaceuticals
amphastar.com
Companies similar to Maia Pharmaceuticals include Meitheal Pharmaceuticals, Eagle Pharmaceuticals, Dawah Pharmaceuticals and Manhattan Pharmaceuticals.
Maia Pharmaceuticals was founded in 2013.
Maia Pharmaceuticals' headquarters is located in Princeton, NJ, US.
Maia Pharmaceuticals' most recent funding round was for $845k (USD) in October 2014.
As of Oct 29, 2014, Maia Pharmaceuticals has raised a total of $845k (USD).
Maia Pharmaceuticals has 8 employees as of Feb 5, 2024.